Magenta Therapeutics Inc (MGTA):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Magenta Therapeutics Inc (MGTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8213)・商品コード:DATA904C8213
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:44
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Magenta Therapeutics Inc (Magenta Therapeutics) formerly HSCTCo Therapeutics Inc, is a clinical-stage biotechnology company focused on developing novel medicines which revolutionizes bone marrow transplant for treating autoimmune diseases, blood cancers and rare genetic diseases. Its product candidates include C100, C200, and C300 which are targeted antibody-drug conjugates used for transplant conditioning methods to reduce hematopoietic stem cells (HSCs) and immune cells in bone marrow; MGTA-M100, for mobilization of hematopoietic stem cells (HSCs); MGTA-456, an allogeneic stem cell therapy that allows expansion of cord blood stem cells; and G100, targeting graft-versus-host disease (GvHD) causing donor T-cells. The company is funded by Third Rock Ventures LLC, and Atlas Venture Inc. Magenta Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Magenta Therapeutics Inc (MGTA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Magenta Therapeutics Raises USD52 Million in Series C Financing 12
Magenta Therapeutics Raises USD50 Million in Series B Financing 14
Magenta Therapeutics Raises USD48.5 Million in Series A Venture Financing 16
Partnerships 17
Magenta Therapeutics Enters into Multi-Target Research Agreement with Heidelberg Pharma 17
Magenta Therapeutics Enters into Development and Manufacturing Agreement with Bachem Americas 18
Magenta Therapeutics Enters into Agreement with University of Minnesota 19
Magenta Therapeutics Enters into Partnership with Be The Match BioTherapies 20
Licensing Agreements 21
Magenta Therapeutics Enters into Licensing Agreement with Novartis for MGTA-456 21
Magenta Therapeutics Enters into a Licensing Agreement with Trianni 22
Magenta Therapeutics Enters into Licensing Agreement with President and Fellows of Harvard College 23
Equity Offering 24
Magenta Therapeutics Raises USD100 Million in IPO of Shares 24
Debt Offering 26
Magenta Therapeutics Raises USD6.5 Million in Private Placement of 6% Convertible Promissory Notes 26
Magenta Therapeutics Raises USD0.5 Million in Private Placement of Convertible Promissory Notes 27
Magenta Therapeutics Inc – Key Competitors 28
Magenta Therapeutics Inc – Key Employees 29
Magenta Therapeutics Inc – Locations And Subsidiaries 30
Head Office 30
Recent Developments 31
Financial Announcements 31
Aug 09, 2018: Magenta Therapeutics reports recent operational progress and second quarter 2018 financial results 31
Corporate Communications 32
Apr 09, 2018: Magenta Therapeutics Appoints Amy Ronneberg to its Board of Directors 32
Apr 06, 2018: Magenta Therapeutics Appoints Amy Ronneberg, President of Be The Match BioTherapies, to Board of Directors 33
Apr 03, 2018: Magenta Therapeutics announces departure of chief operating officer Bastiano Sanna, Ph.D. 34
Feb 21, 2018: Magenta Therapeutics Hires John Davis, MD, MPH, as Chief Medical Officer 35
Oct 24, 2017: Magenta Therapeutics Appoints Alison Lawton, Jeff Albers and Blake Byers to its Board of Directors 36
Legal and Regulatory 37
Sep 24, 2018: Magenta Therapeutics added to Russell 2000 and 3000 Indexes 37
Product News 38
12/11/2017: Magenta’s Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust Neutrophil and Immune Recovery in Two Phase II Clinical Studies 38
Dec 09, 2017: Magenta Therapeutics’ lead targeted antibody drug conjugate shows promising preclinical results for non-genotoxic conditioning for bone marrow transplant 39
05/10/2017: Magenta Therapeutics Announces New Clinical Data on its Lead Expansion Clinical Program, MGTA-456, Presented at American Society of Gene and Cell Therapy Annual Meeting 40
Clinical Trials 41
Apr 05, 2018: Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders 41
Nov 01, 2017: Magenta Therapeutics to Present Clinical Results and Preclinical Research at American Society of Hematology (ASH) Annual Meeting 42
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Magenta Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Magenta Therapeutics Raises USD52 Million in Series C Financing 12
Magenta Therapeutics Raises USD50 Million in Series B Financing 14
Magenta Therapeutics Raises USD48.5 Million in Series A Venture Financing 16
Magenta Therapeutics Enters into Multi-Target Research Agreement with Heidelberg Pharma 17
Magenta Therapeutics Enters into Development and Manufacturing Agreement with Bachem Americas 18
Magenta Therapeutics Enters into Agreement with University of Minnesota 19
Magenta Therapeutics Enters into Partnership with Be The Match BioTherapies 20
Magenta Therapeutics Enters into Licensing Agreement with Novartis for MGTA-456 21
Magenta Therapeutics Enters into a Licensing Agreement with Trianni 22
Magenta Therapeutics Enters into Licensing Agreement with President and Fellows of Harvard College 23
Magenta Therapeutics Raises USD100 Million in IPO of Shares 24
Magenta Therapeutics Raises USD6.5 Million in Private Placement of 6% Convertible Promissory Notes 26
Magenta Therapeutics Raises USD0.5 Million in Private Placement of Convertible Promissory Notes 27
Magenta Therapeutics Inc, Key Competitors 28
Magenta Therapeutics Inc, Key Employees 29

List of Figures
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Magenta Therapeutics Inc (MGTA):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8213)販売に関する免責事項を必ずご確認ください。
★調査レポート[Magenta Therapeutics Inc (MGTA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆